Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTC PINK OTC PINK Primary 
Siemens Healthineers meets full-year earnings forecast
German medical technology company Siemens Healthineers reported a full-year adjusted earnings before interest and taxes (EBIT) and revenue growth in line with analysts' consensus on Wednesday.
Siemens Healthineers: My Current Pick In Medtech Ahead Of Q4 2024
Siemens Healthineers is a company that I have written about a few times in the past, and I already have a bit of a position in SEMHF. My intention, before 4Q24, which is coming out in a few days, is to increase this stake. In this article, I show you why I intend to purchase more in Medtech and why I see a good upside here.
Together with Siemens Healthineers, Varian Highlights Software and Imaging Innovations to Enable Personalized Patient Care at ASTRO 2024
PALO ALTO, Calif.--(BUSINESS WIRE)-- #ASTRO24--Together with Siemens Healthineers, Varian Highlights Software and Imaging Innovations to Enable Personalized Patient Care at ASTRO 2024.
Siemens Healthineers AG (SEMHF) Q3 2024 Earnings Call Transcript
Siemens Healthineers AG (OTCPK:SEMHF) Q3 2024 Earnings Conference Call July 31, 2024 2:30 AM ET Company Participants Marc Koebernick - Head-Investor Relations Bernd Montag - Chief Executive Officer Jochen Schmitz - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi David Adlington - JPMorgan Hugo Solvet - Exane Julien Dormois - Jefferies Julien Ouaddour - Bank of America Robert Davies - Morgan Stanley Sezgi Ozener - HSBC Operator Good morning, ladies and gentlemen, welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.
AI in Medical Diagnostics Market Insights and Forecast, 2024-2033 - Top Ten Competitors Account for 56.02% of the Total Revenue, Led by Siemens Healthineers, Followed Closely by Merative L.P.
Dublin, July 19, 2024 (GLOBE NEWSWIRE) -- The "AI in Medical Diagnostics Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.
Siemens Healthineers: The Upside Is Clear To Me Over The Long Term
Siemens Healthineers reported good revenue growth and margin expansion in Q2 2024, with strong performance in Imaging, Varian, and Advanced Therapies segments. Despite a recent decline in share price, the company maintains a strong balance sheet and confirms full-year outlook for mid-to-high single-digit growth. Analysts have a positive outlook on Healthineers, with price targets ranging from €48 to €75/share and 18 out of 20 analysts recommending a "BUY" or outperform rating.
Siemens Healthineers: Softer Orders A Risk, But The Story Remains Sound
Healthcare capex demand has supported healthy order growth at Siemens Healthineers, as the company leverages new innovative platforms in Imaging (MRI, CT) and radiation oncology (Varian). The Street wants margin leverage and order growth in FQ3'24, and I think there's a good chance of getting both. Diagnostics still needs a lot of work to become more competitive, and a rumored sale/spin may be a better option.
